Sommaire

Numéro précédent | Numéro suivant

• • ·Measles immunisation: time to close the gap

    Page :1

     
• • ·Duration of immune responses after Ebola virus vaccination

    Page :2-3

    Steven B Bradfute

     
• • ·Tenofovir alafenamide for HIV: time to switch?

    Page :3-5

    Shireesha Dhanireddy, Jared M Baeten

     
• • ·Oxantel pamoate and deworming programmes

    Page :5-6

    Mathieu Maheu-Giroux

     
• • ·Artefenomel: a promising new antimalarial drug

    Page :6-8

    Philip J Rosenthal

     
• • ·Do chlorhexidine patient baths prevent catheter-associated urinary tract infections?

    Page :8-9

    Mark E Rupp

     
• • ·An opportunity for further control of hepatitis B in China?

    Page :10-11

    Claudia Vellozzi, Francisco Averhoff

     
• • ·Sanitation and disease—updates are overdue

    Page :11-13

    Joan B Rose, Walter Jakubowski

     
• • ·From START to finish: implications of the START study

    Page :13-14

    Kevin M De Cock, Wafaa M El-Sadr

    
• • ·Camels, MERS-CoV, and other emerging infections in east Africa

    Page :14-15

    Amira Roess, Lauren Carruth, Sally Lahm, Mo Salman

    
• • ·On this year’s cover

    Page :16

    Raffaella Bosurgi

    
• • ·Corrections

    Page :16

    
• • ·Corrections

    Page :16

    
• • ·Corrections

    Page :16

    
• • ·Whole-genome sequencing for the diagnosis of drug-resistant tuberculosis

    Page :17

    Babak Javid, M Estée Török

    
• • ·How to minimise antibiotic resistance

    Page :17-18

    Jung Hun Lee, Kwang Seung Park, Asad Mustafa Karim, Chang-Ro Lee, Sang Hee Lee

     
• • ·Symptoms closely associated with Ebola virus disease

    Page :18-19

    Xudong Gao, Guanghua Rong, Yinying Lu, Xuezhang Duan, Huijuan Duan

    
• • ·Mother-to-child transmission of hepatitis B in sub-Saharan Africa

    Page :19-20

    Yusuke Shimakawa, Coumba Toure-Kane, Maimuna Mendy, Mark Thursz, Maud Lemoine

    
• • ·Elimination of mother-to-child transmission of hepatitis B

    Page :20-21

    Resat Ozaras, Ilker Inanc Balkan, Mucahit Yemisen, Bilgul Mete, Fehmi Tabak

    
• • ·Respiratory co-morbidities in people with HIV

    Page :21

    James Brown, Colette Smith, Margaret Johnson, Marc Lipman, Ibrahim Abubakar

    
• • ·Assessing the quality of tuberculosis care in India

    Page :21-22

    Carolyn Kavita Tauro

    
• • ·Assessing the quality of tuberculosis care in India – Authors’ response

    Page :22

    Jishnu Das, Madhukar Pai

    
• • ·Use of standardised patients to assess quality of tuberculosis care

    Page :23

    Yatin Dholakia, Nerges Mistry, Eunice Lobo, Sheela Rangan

    
• • ·Cholera in Iraq strains the fragile state

    Page :24-25

    Sanjeet Bagcchi

     
• • ·Sex education in China leaves young vulnerable to infection

    Page :26

    Talha Burki

    
• • ·Europe’s migrants face unacceptable humanitarian situation

    Page :27-28

    Sally Hargreaves

     
• • ·Infectious disease surveillance update

    Page :28

    Ruth Zwizwai

    Plan Plan
• • ·Research brief

    Page :29

    Dara Mohammadi

    Plan Plan  
• • ·Genetically modified bacteria could save your life

    Page :30

    Peter Ranscombe

     
• • ·Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial

    Page :31-42

    Milagritos D Tapia, Samba O Sow, Kirsten E Lyke, Fadima Cheick Haidara, Fatoumata Diallo, Moussa Doumbia, Awa Traore, Flanon Coulibaly, Mamoudou Kodio, Uma Onwuchekwa, Marcelo B Sztein, Rezwanul Wahid, James D Campbell, Marie-Paule Kieny, Vasee Moorthy, Egeruan B Imoukhuede, Tommy Rampling, Francois Roman, Iris De Ryck, Abbie R Bellamy, Len Dally, Olivier Tshiani Mbaya, Aurélie Ploquin, Yan Zhou, Daphne A Stanley, Robert Bailer, Richard A Koup, Mario Roederer, Julie Ledgerwood, Adrian V S Hill, W Ripley Ballou, Nancy Sullivan, Barney Graham, Myron M Levine

    Résumé Résumé Plan Plan   
• • ·Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study

    Page :43-52

    Anthony Mills, Jose R Arribas, Jaime Andrade-Villanueva, Giovanni DiPerri, Jan Van Lunzen, Ellen Koenig, Richard Elion, Matthias Cavassini, Jose Valdez Madruga, Jason Brunetta, David Shamblaw, Edwin DeJesus, Chloe Orkin, David A Wohl, Indira Brar, Jeffrey L Stephens, Pierre-Marie Girard, Gregory Huhn, Andrew Plummer, Ya-Pei Liu, Andrew K Cheng, Scott McCallister, GS-US-292-0109 team

    Résumé Résumé Plan Plan   
• • ·Efficacy and safety of oxantel pamoate in school-aged children infected with Trichuris trichiura on Pemba Island, Tanzania: a parallel, randomised, controlled, dose-ranging study

    Page :53-60

    Wendelin Moser, Said M Ali, Shaali M Ame, Benjamin Speich, Maxim Puchkov, Jörg Huwyler, Marco Albonico, Jan Hattendorf, Jennifer Keiser

    Résumé Résumé Plan Plan   
• • ·Antimalarial activity of artefenomel (OZ439), a novel synthetic antimalarial endoperoxide, in patients with Plasmodium falciparum and Plasmodium vivax malaria: an open-label phase 2 trial

    Page :61-69

    Aung Pyae Phyo, Podjanee Jittamala, François H Nosten, Sasithon Pukrittayakamee, Mallika Imwong, Nicholas J White, Stephan Duparc, Fiona Macintyre, Mark Baker, Jörg J Möhrle

    Résumé Résumé Plan Plan   
• • ·Effect of body surface decolonisation on bacteriuria and candiduria in intensive care units: an analysis of a cluster-randomised trial

    Page :70-79

    Susan S Huang, Edward Septimus, Mary K Hayden, Ken Kleinman, Jessica Sturtevant, Taliser R Avery, Julia Moody, Jason Hickok, Julie Lankiewicz, Adrijana Gombosev, Rebecca E Kaganov, Katherine Haffenreffer, John A Jernigan, Jonathan B Perlin, Richard Platt, Robert A Weinstein, Agency for Healthcare Research and Quality (AHRQ) DEcIDE Network and Healthcare-Associated Infections Program, and the CDC Prevention Epicenters Program

    Résumé Résumé Plan Plan   
• • ·Seroepidemiology of hepatitis B virus infection in 2 million men aged 21–49 years in rural China: a population-based, cross-sectional study

    Page :80-86

    Jue Liu, Shikun Zhang, Qiaomei Wang, Haiping Shen, Man Zhang, Yiping Zhang, Donghai Yan, Min Liu

    Résumé Résumé Plan Plan  
• • ·Effect of sanitation and water treatment on intestinal protozoa infection: a systematic review and meta-analysis

    Page :87-99

    Benjamin Speich, David Croll, Thomas Fürst, Jürg Utzinger, Jennifer Keiser

    Résumé Résumé Plan Plan   
• • ·Mycetoma: a unique neglected tropical disease

    Page :100-112

    Eduard E Zijlstra, Wendy W J van de Sande, Oliverio Welsh, El Sheikh Mahgoub, Michael Goodfellow, Ahmed H Fahal

    Résumé Résumé Plan Plan   
• • ·Tularaemia: clinical aspects in Europe

    Page :113-124

    Max Maurin, Miklós Gyuranecz

    Résumé Résumé Plan Plan  
• • ·The scenario approach for countries considering the addition of oral cholera vaccination in cholera preparedness and control plans

    Page :125-129

    Jacqueline Deen, Lorenz von Seidlein, Francisco J Luquero, Christopher Troeger, Rita Reyburn, Anna Lena Lopez, Amanda Debes, David A Sack

    Résumé Résumé Plan Plan
• • ·The Ebola Vaccine Team B: a model for promoting the rapid development of medical countermeasures for emerging infectious disease threats

    Page :e1

    Michael Osterholm, Kristine Moore, Julie Ostrowsky, Kathleen Kimball-Baker, Jeremy Farrar, Wellcome Trust-CIDRAP Ebola Vaccine Team B †

    Résumé Résumé Plan Plan
• • ·Classic Whipple’s disease diagnosed by ¹⁸F-fluorodeoxyglucose PET

    Page :130

    Jean-Christophe Lagier, Serge Cammilleri, Didier Raoult